George Vande Woude

George Vande Woude was an American virologist and cancer researcher noted for his work on oncogenes and growth factor receptors. He led programs at the National Cancer Institute and contributed to molecular oncology through studies that linked viral oncogenes to human cancer mechanisms. His career connected institutions such as Wayne State University, Netherlands Cancer Institute, and the National Institutes of Health.

Early life and education

Born in Zeeland, Michigan, Vande Woude completed undergraduate studies at Calvin University and pursued doctoral studies at University of Colorado Boulder where he trained in molecular biology and virology. He undertook postdoctoral work at Johns Hopkins University and collaborated with researchers at the Rockefeller University and the Pasteur Institute during early stages of his career. His training involved interactions with laboratories associated with figures like Howard Temin and Temin Laboratory-era researchers, and he developed expertise in viral transformation, cell signaling, and oncogene function.

Research career

Vande Woude joined the National Cancer Institute where he directed programs in tumor biology and later served as chief of the Laboratory of Molecular Oncology. His laboratory exploited tools from molecular cloning, DNA sequencing, and Southern blotting to identify and characterize oncogenes derived from oncogenic viruses such as Rous sarcoma virus and hepatitis B virus models. He collaborated with investigators at the University of California, Berkeley, Massachusetts Institute of Technology, and the University of Michigan and maintained ties with European centers including the Netherlands Cancer Institute and the European Molecular Biology Laboratory. Vande Woude's team integrated approaches from labs associated with Michael Bishop and Harold Varmus to map signaling pathways and receptor tyrosine kinases that regulate cell proliferation and motility.

Major discoveries and contributions

Vande Woude is widely credited for the identification and characterization of the MET proto-oncogene, linking a receptor tyrosine kinase to invasive growth and human cancers; this work connected to studies involving hepatocyte growth factor and the scatter factor concept. His findings bridged viral oncology from studies on avian sarcoma viruses to human malignancies such as lung cancer, colorectal cancer, and glioblastoma. He contributed to understanding how alterations in signaling through receptors like MET and interactions with pathways involving RAS, PI3K, and STAT3 drive tumor progression. His research influenced targeted therapy development exemplified by kinase inhibitors used in trials at institutions like MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center, and informed biomarker strategies used by agencies such as the Food and Drug Administration. Vande Woude also mentored scientists who later joined faculties at places like Harvard University, Stanford University, and University of Pennsylvania.

Awards and honors

During his career, he received recognition from organizations including the American Association for Cancer Research, the National Academy of Sciences, and the American Society for Clinical Investigation. He was elected to bodies such as the Institute of Medicine and received awards that place him alongside laureates like James Watson, Sydney Brenner, and Richard Roberts. His laboratory's work was cited in reviews published in journals associated with Cell, Nature, and Science, and he participated in advisory committees linked to the National Institutes of Health and international consortia including European Organization for Research and Treatment of Cancer.

Personal life and legacy

Vande Woude balanced a scientific career with family life in Maryland and maintained connections to his Michigan roots, including ties to Grand Rapids and Zeeland Public Library-area communities. His legacy persists through the MET-centric paradigm in cancer biology, through trainees who hold positions at institutions such as Columbia University and Yale University, and through translational programs at the National Cancer Institute that continue to pursue targeted therapeutics. His contributions are commemorated in memorials organized by research organizations including the American Association for Cancer Research and institutional histories at the National Institutes of Health.

Category:1935 births Category:2021 deaths Category:American virologists Category:National Cancer Institute people